Ribon | search
Click here to view Ribon news from 60+ newspapers.
Bookmark or Share- Ribon taps former Novartis VP, Flagship partner Raman as CEOCellular-stress-focused biotech Ribon Therapeutics has hired former Novartis VP and Flagship Pioneering Senior Partner Prakash Raman, Ph.D., as its new CEO. Raman most recently was senior partner...
- Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor ...Ribon Therapeutics has raised $65 million to advance a pipeline led by a PARP7 inhibitor deeper into the clinic. The financing positions Ribon to build on work to target stress support pathways...
- Ribon Therapeutics Announces $25 Million Equity Investment from PfizerRibon Therapeutics Announces $25 Million Equity Investment from Pfizer. Proceeds will support development of lead clinical programs, RBN-2397 and RBN-3143, while advancing early-stage pipeline derived from Ribon’s BEACON+ platform.
- Home – Ribon TherapeuticsRibon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON + (Blocking the Enzyme Activity Component of NAD +) platform. Learn More
- News – Ribon TherapeuticsRibon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis. Cambridge, MA – March 9, 2023 – Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced dosing the first … Learn More
More
